Organization

Instituto de Salud Carlos III

4 abstracts

Abstract
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
Org: Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario Son Espases, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,
Abstract
The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer.
Org: INCLIVA Biomedical Research Institute, University of Valencia, Instituto Carlos III, CIBERONC, Biostatistics Unit,
Abstract
Obesity and toxic habits as avoidable determinants of chronic peripheral neuropathy induced by chemotherapy (NPCIQ): NeuroPredict project.
Org: Reina Sofía University Hospital, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, CIBERONC,